Dr. Anna Wojciechowska

Dr. Anna Wojciechowska is a distinguished medical oncologist at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland's leading cancer treatment and research center. With 18 years of clinical experience, she has built a reputation for excellence in the management of breast and gynecological cancers.

She completed an advanced oncology fellowship at the Institut Curie in Paris, France, gaining expertise in precision medicine and molecular-targeted therapies. Dr. Wojciechowska returned to Poland to champion the introduction of next-generation sequencing (NGS)-guided treatment protocols at her institute.

She is deeply committed to multidisciplinary oncology, working closely with surgical oncologists, radiation therapists, and pathologists to develop individualized treatment plans. Her research into HER2-positive breast cancer has been recognized at major European oncology congresses.

Dr. Wojciechowska is known for her empathetic approach to patient care, helping patients and families navigate the complexities of cancer diagnosis and treatment with clarity and compassion. She regularly sees international patients seeking second opinions and specialized oncology treatment in Poland.

Dr. Wojciechowska graduated with honors from Warsaw Medical University in 2003. She completed her internal medicine residency at the Central Teaching Hospital in Warsaw before specializing in oncology. She undertook a two-year advanced fellowship at the Institut Curie, Paris (2008–2010), where she focused on breast cancer molecular subtypes and targeted therapies. She was awarded her PhD in 2011 for research on predictive biomarkers in HER2-positive breast cancer. She is a member of the European Society for Medical Oncology (ESMO) and is certified by the Polish Medical Chamber in oncology.

Dr. Wojciechowska's primary clinical focus is on breast and gynecological cancers, with expertise in HER2-positive disease, triple-negative breast cancer, and hormone receptor-positive tumors. She designs and administers chemotherapy protocols, targeted therapy regimens (trastuzumab, pertuzumab, CDK4/6 inhibitors), and immunotherapy combinations. She is skilled in interpreting molecular profiling reports and translating genomic data into actionable treatment plans. She also manages colorectal cancer and lymphoma cases as part of a multidisciplinary team and is experienced in palliative oncology care.

Dr. Wojciechowska has published over 40 peer-reviewed papers in journals including the Annals of Oncology and Breast Cancer Research. Her research program focuses on predictive biomarkers for HER2-targeted therapy, neoadjuvant chemotherapy outcomes, and the role of liquid biopsy in treatment monitoring. She is a principal investigator in several international clinical trials and collaborates with research groups in France, Germany, and the UK.

Dr. Wojciechowska speaks Polish, English, and French and has extensive experience treating international cancer patients seeking second opinions and treatment in Poland. The Maria Sklodowska-Curie Institute offers a dedicated international patient coordination service with document translation, treatment summaries in English, and telemedicine follow-up appointments. Poland's oncology centers offer treatment costs significantly lower than Western Europe while maintaining EU-standard quality and access to the latest approved therapies.

Dr. Wojciechowska received the Polish Society of Clinical Oncology Award for Research Excellence in 2019 and was named Young Investigator of the Year by ESMO in 2012. She has been featured in Wprost magazine's ranking of Poland's Top 100 Physicians. In 2023, she received the Institute's Director's Award for her leadership in establishing a molecular tumor board at the Maria Sklodowska-Curie Institute.